Skip to main content
رجوع
CGON logo

CG Oncology, Inc. Common stock

جودة البيانات: 100%
CGON
NASDAQ Healthcare Biotechnology
KWD 64.96
▼ KWD 0.12 (-0.18%)
القيمة السوقية: 5.48B
نطاق اليوم
KWD 63.97 KWD 66.30
نطاق 52 أسبوعًا
KWD 14.80 KWD 69.35
حجم التداول
1,804,264
متوسط 50 يوم / 200 يوم
KWD 56.68 / KWD 39.90
الإغلاق السابق
KWD 65.08

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -34.1 0.4
P/B 7.3 2.9
ROE % -21.7 3.7
Net Margin % -3985.0 3.9
Rev Growth 5Y % -21.0 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 79.000 +21.6%
Low: KWD 70.000 High: KWD 93.000
ربحية السهم المستقبلية
-KWD 2.419
الإيرادات المقدّرة
15 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 6.523
KWD 0.799 – KWD 17.442
1.4 B 3
FY2029 KWD 3.219
KWD 0.394 – KWD 8.607
910 M 3
FY2028 KWD 0.223
-KWD 1.716 – KWD 3.820
460 M 9

النقاط الرئيسية

Revenue declined -20.97% annually over 5 years
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -132.48M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 275.67%
Capital efficient — spends only 3.32% of revenue on capex

النمو

Revenue Growth (5Y)
-20.97%
Revenue (1Y)254.70%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-21.67%
ROIC-18.84%
Net Margin-3985.02%
Op. Margin-4722.13%

الأمان

Debt / Equity
0.01
Current Ratio24.63
Interest Coverage0.00

التقييم

P/E Ratio
-34.07
P/B Ratio7.29
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 254.70% Revenue Growth (3Y) 345.02%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -20.97% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.04M Net Income (TTM) -161.00M
ROE -21.67% ROA -20.34%
Gross Margin -15.02% Operating Margin -4722.13%
Net Margin -3985.02% Free Cash Flow (TTM) -132.48M
ROIC -18.84% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 24.63
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -34.07 P/B Ratio 7.29
P/S Ratio 1357.65 PEG Ratio -0.42
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 5.48B Enterprise Value 5.46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.04M 1.14M 204,000.0 191,000.0 10.36M
Net Income -161.00M -88.04M -48.61M -35.44M -12.84M
EPS (Diluted) -2.08 -1.41 -1.02 -0.66 -0.28
Gross Profit -607,000.0 1.14M 204,000.0 176,000.0 10.35M
Operating Income -190.77M -114.67M -55.45M -35.25M -12.61M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 791.59M 754.80M 199.30M 147.75M 58.69M
Total Liabilities 38.99M 21.42M 14.51M 22.57M 18.44M
Shareholders' Equity 752.60M 733.38M 184.79M 125.18M 40.25M
Total Debt 7.02M 238,000.0 1.03M 15.94M 15.13M
Cash & Equivalents 32.49M 257.07M 8.27M 88.14M 53.61M
Current Assets 759.48M 754.21M 194.12M 147.21M 58.41M
Current Liabilities 30.84M 21.37M 14.25M 15.43M 5.98M